Back Tuberculosis

Pipeline Report Shows Good Prospects for People with HIV, HCV, and TB

An updated summary of experimental therapies for HIV, hepatitis C virus (HCV), and tuberculosis, produced by treatment advocates with i-Base and TAG, shows rapid progress in therapies for HCV and steady progress in the area of HIV.


Read more:

Simpler TB Therapy Prevents Active Disease in HIV+ People

A combination regimen taken once-weekly for 3 months works as well as a single drug taken daily for 6 months at preventing development of full-blown tuberculosis (TB) disease among HIV positive adults infected with tuberculosis bacteria. alt

Read more:

Shorter Treatment More Effective for Latent TB

Rifapentine plus isoniazid administered once-weekly for 3 months to treat latent tuberculosis worked better than daily isoniazid for 9 months, with fewer premature treatment discontinuations, researchers reported at the recent American Thoracic Society meeting.

Read more:

Updated CDC HIV and TB Fact Sheet

The Centers for Disease Control and Prevention (CDC) has issued a revised fact sheet on tuberculosis in people with HIV.

Read more:

TB Fixed-dose Coformulation Works as Well as Separate Drugs

A 4-drug combination containing rifampicin, isoniazid, pyrazinamide, and ethambutol treats pulmonary tuberculosis (TB) as effectively as individual medications.

Read more: